详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: Asthma, COPD, lung cancer, PF, and PH

41| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China [2]Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

出处：

DOI：

ISSN：

关键词： Epigenetics Type I PRMTs Asthma COPD Lung cancer Pulmonary fibrosis Pulmonary hypertension

摘要：

Pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (PF), pulmonary hypertension (PH), and lung cancer, seriously impair the quality of lives of patients. A deeper understanding of the occurrence and development of the above diseases may inspire new strategies to remedy the scarcity of treatments. Type I protein arginine methyltransferases (PRMTs) can affect processes of inflammation, airway remodeling, fibroblast proliferation, mitochondrial mass, and epithelial dysfunction through substrate methylation and non-enzymatic activity, thus affecting the occurrence and development of asthma, COPD, lung cancer, PF, and PH. As potential therapeutic targets, inhibitors of type I PRMTs are developed, moreover, representative compounds such as GSK3368715 and MS023 have also been used for early research. Here, we collated structures of type I PRMTs inhibitors and compared their activity. Finally, we highlighted the physiological and pathological associations of type I PRMTs with asthma, COPD, lung cancer, PF, and PH. The developing of type I PRMTs modulators will be beneficial for the treatment of these diseases.Copyright © 2024 Elsevier Inc. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区医学：研究与实验 2 区药学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子： 5.2 最新[2023版] 5.3 最新五年平均 5.2 出版当年[2023版] 0 出版当年五年平均 5.2 出版前一年[2023版]

第一作者：

第一作者机构： [1]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis [2]Myeloid-derived suppressor cells and pulmonary hypertension [3]Current therapeutic strategies for respiratory diseases using mesenchymal stem cells. [4]Mitochondrial quality control in lung diseases: current research and future directions [5]Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models [6]Pulmonary arterial hypertension in a Kartagener syndrome patient: Treatment with beraprost sodium [7]Pulmonary arterial hypertension associated with rare cause of ANCA-associated vasculitis misdiagnosed as idiopathic one [8]Sirtuin 6 ameliorates bleomycin-induced pulmonary fibrosis via activation of lipid catabolism [9]XBP1S Regulates MUC5B in a Promoter Variant-Dependent Pathway in Idiopathic Pulmonary Fibrosis Airway Epithelia. [10]养阴清肺方对钴60照射后肺成纤维细胞增殖的影响